Last week at the World Vaccine Congress Dr Michael Kurilla, Director, Office of BioDefense Research Affairs & Associate Director for BioDefense Product Development at DMID, NIAID, NIH, DHHS delivered a presentation on Enhancing existing vaccines, developing technologies for biodefence vaccines.
Dr Kurilla talked about the aspect of vaccination and how to enhance vaccination technologies. The current development path for this kind of vaccines was outlined including NIH scientific activities, transition partners and commercial development activities. Funding support is not adequate so NIAID developed the critical infrastructure including services.
The Public Health Emergency Medical Countermeasures Enterprise Review published in 2010 was discussed.
Focus on broad spectrum approaches including products, product enhancements (vaccine adjuvants, temperature stabilization, alternative delivery devices) and production platforms.
Good biodefense vaccine should have:
- Long shelf life
- Rapid onset of immunity
- Post exposure prophylaxis-minimal training necessary
-surge capacity for production